The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
SERENA: 3-year interim analysis of secukinumab in Greek patients with PsA and ankylosing spondylitis
Secukinumab, a fully human anti-IL-17A mAb, is approved by the EMA for several PsO/PsA indications. Real-world retention rates represent an important measure of long-term efficacy and safety, as well as patient satisfaction, in chronic conditions; and together , can guide clinical decisions. Real-world data on secukinumab retention rates are limited in Europe. The recently completed, longitudinal, observational, multinational SERENA study (CAIN457 A3403) evaluated long-term retention of secukinumab in patients with PsA and AS across 17 countries in Europe, Israel, and Russia. A 3-year interim analysis from patients enrolled in the SERENA study treated in Greece was published by Bounas et al. in Rheumatology International. Patients with PsA (n = 214) and AS (n = 81) enrolled at Greek centers between October 19, 2017, and October 29, 2018, were included in the analysis. The primary outcome was secukinumab retention rates. Secondary outcomes included effectiveness and safety.
|
Key learnings |
The secukinumab retention rates at 1, 2, and 3 years were 87.1%, 76.9%, and 74.0% in the PsA cohort and 89.9%, 80.5%, and 77.3% in the AS cohort, respectively. |
In the PsA cohort, the presence of tender or swollen joints, dactylitis, and enthesitis reduced from 49.5%, 6.1%, and 16.4% at enrollment to 19.2%, 1.4%, and 3.4% at 3 years, respectively. |
In the AS cohort, the mean ASDAS-CRP was reduced from 2.3 mg/L at enrollment to 1.7 mg/L at 3 years, with 40.9% of patients having inactive disease (<1.3 mg/L). |
In the PsA and AS cohort, TEAEs occurred in 13.3% and 13.6% of patients, respectively. The most common reasons for secukinumab discontinuation were lack of drug effectiveness (37.1%) and AEs (27.1%). |
Secukinumab demonstrates long-term retention rates, sustained effectiveness, and safety. The findings strengthen emerging data from other observational studies and support the use of secukinumab in the treatment of PsA and AS. |
Abbreviations: AE, adverse event; AS, ankylosing spondylitis; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score with C-reactive protein; EMA, European Medicines Agency; PsA, psoriatic arthritis; PsO, psoriasis; TEAE, treatment-emergent adverse event.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
